Hoffman D A, McConahey W M, Fraumeni J F, Kurland L T
Int J Epidemiol. 1982 Sep;11(3):218-24. doi: 10.1093/ije/11.3.218.
A retrospective cohort study of women treated for hyperthyroidism at the Mayo Clinic was conducted to evaluate the risk of cancer according to type of therapy. One or more years after the start of treatment, there were 105 cases of cancer observed among 1005 women treated with radioiodine (131I) and 247 cases among 2141 women treated with surgery. No difference was observed between the two study groups for total cancer incidence (RR = 1.0), breast cancer (RR = 0.8), or leukaemia (RR = 0.6). Although based on small numbers of cases, an elevated risk of cancer was observed in organs that concentrate 131I (salivary glands, digestive tract, kidney and bladder) (RR = 1.8). While the findings are suggestive, they indicate the need for larger surveys to evaluate the carcinogenic potential of 131I.
在梅奥诊所进行了一项针对接受甲亢治疗的女性的回顾性队列研究,以评估根据治疗类型的癌症风险。治疗开始一年或更长时间后,在接受放射性碘(131I)治疗的1005名女性中观察到105例癌症病例,在接受手术治疗的2141名女性中观察到247例癌症病例。两个研究组在总癌症发病率(RR = 1.0)、乳腺癌(RR = 0.8)或白血病(RR = 0.6)方面未观察到差异。尽管基于病例数量较少,但在摄取131I的器官(唾液腺、消化道、肾脏和膀胱)中观察到癌症风险升高(RR = 1.8)。虽然这些发现具有提示性,但它们表明需要进行更大规模的调查来评估131I的致癌潜力。